Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance

J Thromb Haemost. 2022 Nov;20(11):2646-2655. doi: 10.1111/jth.15848. Epub 2022 Sep 2.

Abstract

Background: The diagnosis of heparin-induced thrombocytopenia (HIT) requires functional assays to demonstrate that platelet factor 4 (PF4)-specific antibodies activate platelets, typically when therapeutic heparin (H) concentrations are tested ("classical" pattern). Some HIT samples also activate platelets without heparin ("atypical" pattern), but with unclear clinical significance.

Objectives: We aimed to assess whether platelet activation pattern and some characteristics of PF4-specific antibodies were associated with the severity of HIT.

Patients/methods: Serotonin release assay (SRA) pattern of 81 HIT patients were analyzed and compared with their clinical and biological data, including levels of anti-PF4/H immunoglobulin G (IgG) and anti-PF4 IgG in 47 of them.

Results: Higher anti-PF4/H IgG titers were measured in patients with an "atypical" SRA (optical density 2.52 vs. 1.94 in those with a "classical" pattern, p < .001). Patients of both groups had similar platelet count (PC) nadir and time to recovery, but those with an "atypical" SRA more frequently developed thrombotic events (69% vs. 34%, p = .037). Significant levels of anti-PF4 IgG were detected in both groups (38% and 61%, respectively). Whatever the SRA pattern, a lower PC nadir (35 vs. 53 G/L, p = .006) and a longer PC recovery time (6 vs. 3 days, p = .015) were evidenced in patients with anti-PF4 antibodies, compared with those with anti-PF4/H IgG only.

Conclusions: An atypical SRA pattern with elevated anti-PF4/H IgG titers seems associated with an increased risk of thrombosis in HIT. IgG antibodies to native PF4 may contribute to more severe and persistent thrombocytopenia, and their detection could be useful in clinical practice.

Keywords: antibody; platelet factor 4; platelets; serotonin release assay; thrombocytopenia; thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Heparin / adverse effects
  • Humans
  • Immunoglobulin G
  • Immunologic Factors / adverse effects
  • Platelet Factor 4
  • Serotonin
  • Thrombocytopenia* / chemically induced
  • Thrombocytopenia* / diagnosis
  • Thrombosis* / chemically induced
  • Thrombosis* / complications
  • Thrombosis* / diagnosis

Substances

  • Anticoagulants
  • Heparin
  • Immunoglobulin G
  • Immunologic Factors
  • Platelet Factor 4
  • Serotonin
  • PF4 protein, human